Burow Kristina — SEC insider filings

SEC reporting owner CIK 1569248. 65 insider filings on record with FilingPulse; latest filed 2026-11-05.

Transaction summary — filings shown

Covers the 50 most recent of 65 filings on record, filed 2021-08-09 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prime Medicine, Inc. (PRME)10% owner34 legs · 7,030,300 sh · $43,599,990—6
Metsera, Inc. (MTSR)Director32 legs · 2,222,222 sh · $39,999,996—16
Lyell Immunopharma, Inc. (LYEL)10% owner22 legs · 2,809,352 sh · $37,499,977——
Neumora Therapeutics, Inc. (NMRA)Director, 10% owner1420 legs · 3,922,764 sh · $36,430,001—28
Kardigan, Inc. (KARD)Director, 10% owner21 leg · 1,250,000 sh · $20,000,000—4
Aspen Neuroscience, Inc. (ASPE)10% owner23 legs · 1,333,333 sh · $19,999,995—18
Seaport Therapeutics, Inc. (SPTX)10% owner11 leg · 1,100,000 sh · $19,800,000—4
Sana Biotechnology, Inc. (SANA)10% owner13 legs · 1,818,181 sh · $9,999,996——
Boundless Bio, Inc. (BOLD)10% owner42 legs · 200,000 sh · $3,200,0001 leg · 16,000 sh · $39,84014
CITY THERAPEUTICS, INC. (CTY)10% owner21 leg · 170,000 sh · $3,060,000—6

+5 more issuers among the filings shown — every filing appears in the table below.

Insider filings — Burow Kristina

FiledFormIssuerReported transactionsSource
2026-11-054Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 moreEDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT
Holdings only — no transactions reportedEDGAR
2026-10-194CITY THERAPEUTICS, INC. (CTY)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Conversion (C): 3,000,000 (derivative) @ $0 · Conversion (C): 4,991,633 (derivative) @ $0 · +1 moreEDGAR
2026-10-153CITY THERAPEUTICS, INC. (CTY)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Holdings only — no transactions reportedEDGAR
2026-07-064Boundless Bio, Inc. (BOLD)
jointly with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN
Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0EDGAR
2026-07-064Scholar Rock Holding Corp (SRRK)Sale (S): 2,105 @ $53.49 · Sale (S): 948 @ $54.28EDGAR
2026-06-244Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
Purchase (P): 1,250,000 @ $16EDGAR
2026-06-224Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative)EDGAR
2026-06-084Scholar Rock Holding Corp (SRRK)Grant/award (A): 6,839 @ $0 · Grant/award (A): 4,310 (derivative) @ $0EDGAR
2026-05-294Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2026-05-044Seaport Therapeutics, Inc. (SPTX)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0EDGAR
2026-04-244Scholar Rock Holding Corp (SRRK)Option exercise (M): 7,800 @ $26.78 · Option exercise (M): 28,000 @ $4.75 · Option exercise (M): 36,000 @ $9.11 · Option exercise (M): 18,000 @ $8.36 · Option exercise (M): 7,800 (derivative) @ $0 · Option exercise (M): 28,000 (derivative) @ $0 · +2 moreEDGAR
2026-03-094Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 488,090 @ $25.61EDGAR
2025-11-134Metsera, Inc. (MTSR)Disposition to issuer (D): 2,688 · Disposition to issuer (D): 17,070,904 · Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Grant/award (A): 2,688 (derivative) · +2 moreEDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-014Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 3,030,300 @ $3.30EDGAR
2025-06-234Boundless Bio, Inc. (BOLD)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2025-05-304Neumora Therapeutics, Inc. (NMRA)Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative) · Grant/award (A): 80,000 (derivative) @ $0EDGAR
2025-05-304Scholar Rock Holding Corp (SRRK)Sale (S): 1,000 @ $29.24 · Sale (S): 4,400 @ $29.83EDGAR
2025-05-234Scholar Rock Holding Corp (SRRK)Grant/award (A): 7,632 @ $0 · Grant/award (A): 9,206 (derivative) @ $0EDGAR
2025-05-224Metsera, Inc. (MTSR)Grant/award (A): 16,125 (derivative) @ $0EDGAR
2025-02-184Neumora Therapeutics, Inc. (NMRA)Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative)EDGAR
2025-02-034Metsera, Inc. (MTSR)Conversion (C): 16,006,949 · Purchase (P): 1,432,224 @ $18 · Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 moreEDGAR
2024-07-014Scholar Rock Holding Corp (SRRK)Grant/award (A): 13,500 @ $0 · Grant/award (A): 18,000 (derivative) @ $0EDGAR
2024-06-144Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 20,100 @ $0 · Grant/award (A): 28,571 (derivative) @ $0EDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN
Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0EDGAR
2024-04-044Boundless Bio, Inc. (BOLD)Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 moreEDGAR
2024-03-294Boundless Bio, Inc. (BOLD)Grant/award (A): 26,438 (derivative) @ $0EDGAR
2024-02-204Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 3,200,000 @ $6.25EDGAR
2024-02-124Sana Biotechnology, Inc. (SANA)
jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN
Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50EDGAR
2023-12-264Scholar Rock Holding Corp (SRRK)Other (J): 291,906 @ $0 · Other (J): 5,339 @ $0EDGAR
2023-12-124Neumora Therapeutics, Inc. (NMRA)Other (J): 703,061 · Other (J): 1,176,593 · Other (J): 13,997EDGAR
2023-11-154Neumora Therapeutics, Inc. (NMRA)Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98EDGAR
2023-11-134Neumora Therapeutics, Inc. (NMRA)Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75EDGAR
2023-11-074Neumora Therapeutics, Inc. (NMRA)Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50EDGAR
2023-09-294Neumora Therapeutics, Inc. (NMRA)Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98EDGAR
2023-09-274Neumora Therapeutics, Inc. (NMRA)Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31EDGAR
2023-09-254Neumora Therapeutics, Inc. (NMRA)Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65EDGAR
2023-09-204Neumora Therapeutics, Inc. (NMRA)Conversion (C): 13,620 · Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · +7 moreEDGAR
2023-09-184Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 46,455 (derivative) @ $0EDGAR
2023-08-104DA32 Life Science Tech Acquisition Corp. (DALS)
jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, GILLIS STEVEN
Other (J): 1,600,000EDGAR
2023-06-234Scholar Rock Holding Corp (SRRK)Grant/award (A): 36,000 (derivative) @ $0EDGAR
2023-06-094Gossamer Bio, Inc. (GOSS)Grant/award (A): 35,000 (derivative) @ $0EDGAR
2023-06-084Beam Therapeutics Inc. (BEAM)Grant/award (A): 16,532 (derivative) @ $0EDGAR
2022-10-264Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN
Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 moreEDGAR
2022-09-024Beam Therapeutics Inc. (BEAM)Grant/award (A): 10,391 (derivative) @ $0EDGAR
2022-07-154Gossamer Bio, Inc. (GOSS)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2022-05-274Scholar Rock Holding Corp (SRRK)Grant/award (A): 28,000 (derivative) @ $0EDGAR
2021-08-094DA32 Life Science Tech Acquisition Corp. (DALS)
jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, GILLIS STEVEN
Other (J): 701,250 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1569248 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs